Pamela Demain is Executive Director, Transactions, Business Development and Licensing, Merck & Co., Inc. She has been at Merck for over 30 years. For the past 19 years, she has been responsible for negotiating transactions with companies, universities and institutions worldwide, including arrangements for compounds, research collaborations, patents, formulations and research platform technologies.
Pam also heads up the relationship development area, which includes responsibility for Merck’s partnering outreach program, initiating new business development opportunities, and building relationships with companies and universities worldwide. Since 2000, she has been instrumental in the strategic transformation of Merck from an inward-looking to an outward-facing company focused on partnerships with companies and universities worldwide.
Prior to her current position, Ms. Demain was in charge of the Business Information & Research Department in the Worldwide Human Health Marketing area of Merck, providing global strategic decision support for all of Merck’s new and in-line products.
Previous positions at Merck include 13 years in Corporate Planning, Marketing Communications, and Product Management, where she was responsible for the worldwide launch of PRIMAXIN/TIENAM. She joined Merck in 1981 as part of the MBA management training program.
Pamela’s pharmaceutical career began in the natural products laboratory of Gruppo Lepetit, an Italian pharmaceutical company, which was then a subsidiary of the Dow Chemical Company. Ms. Demain is a graduate of the University of Massachusetts at Amherst and holds an M.B.A. in International Business from The American University in Washington, D.C., and is a Certified Licensing Professional (CLP).
Pam has been on the Board of Trustees for the Licensing Executive Society (USA & Canada) since 2006 and is currently President-Elect. Her previous positions on the Board have been VP for Communications, Regional VP for the US, and Trustee for Partnering. Her most recent accomplishments include the Life Science Sector Strategic Initiative and establishing the LES Insights weekly e-newsletter. She has been a member of the LES Life Sciences Committee since 2003. In 2012, she was honored by LES with the Frank Barnes Mentoring Award. In September 2013, Pam joined the Board of BioNJ.
Current role